MX2013005507A - Metodos para tratamiento de tumores. - Google Patents

Metodos para tratamiento de tumores.

Info

Publication number
MX2013005507A
MX2013005507A MX2013005507A MX2013005507A MX2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A MX 2013005507 A MX2013005507 A MX 2013005507A
Authority
MX
Mexico
Prior art keywords
treating tumors
methods
pak1
hyper
administering
Prior art date
Application number
MX2013005507A
Other languages
English (en)
Inventor
Klaus P Hoeflich
Hartmut Koeppen
Christy C Ong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013005507A publication Critical patent/MX2013005507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para tratar tumores en donde PAK1 es sobre-expresado o amplificado al co-administrar un inhibidor PAK1 y un segundo agente anti-hiperproliferativo.
MX2013005507A 2010-11-17 2011-11-14 Metodos para tratamiento de tumores. MX2013005507A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41467110P 2010-11-17 2010-11-17
US201161523062P 2011-08-12 2011-08-12
PCT/EP2011/070008 WO2012065935A1 (en) 2010-11-17 2011-11-14 Methods of treating tumors

Publications (1)

Publication Number Publication Date
MX2013005507A true MX2013005507A (es) 2013-07-17

Family

ID=44993549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005507A MX2013005507A (es) 2010-11-17 2011-11-14 Metodos para tratamiento de tumores.

Country Status (9)

Country Link
EP (1) EP2640369A1 (es)
JP (1) JP2013542965A (es)
KR (1) KR20130121122A (es)
CN (1) CN103298461A (es)
BR (1) BR112013012175A2 (es)
CA (1) CA2817133A1 (es)
MX (1) MX2013005507A (es)
RU (1) RU2013126036A (es)
WO (1) WO2012065935A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
IN2015DN01328A (es) 2012-09-19 2015-07-03 Novartis Ag
WO2014152358A2 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
EP3416623B1 (en) 2016-02-15 2021-08-11 University of Georgia Research Foundation, Inc. Ipa-3-loaded liposomes and methods of use thereof
KR102351270B1 (ko) * 2016-06-16 2022-01-14 하얼빈 젠바오 파마슈티컬 컴퍼니, 리미티드 Akt 억제제인 디히드로피라졸로아제핀계 화합물
WO2020235973A1 (ko) * 2019-05-22 2020-11-26 주식회사 보로노이 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365245T3 (es) 2005-01-10 2011-09-27 Pfizer, Inc. Pirrolopirazoles, potentes inhibidores de quinasas.
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AP2369A (en) 2005-12-21 2012-02-29 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
EP2640369A1 (en) 2013-09-25
WO2012065935A1 (en) 2012-05-24
CA2817133A1 (en) 2012-05-24
JP2013542965A (ja) 2013-11-28
RU2013126036A (ru) 2014-12-27
KR20130121122A (ko) 2013-11-05
CN103298461A (zh) 2013-09-11
BR112013012175A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
WO2012142498A3 (en) Mif inhibitors and their uses
TN2015000423A1 (en) Variants of tissue inhibitor of metalloproteinase type three (tipm-3), compositions and methods
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
MX2017003358A (es) Compuestos novedosos.
SG190819A1 (en) Nampt and rock inhibitors
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MX2013003594A (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl.
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
IN2012DN03883A (es)
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
GB201103062D0 (en) Method
MX2013005507A (es) Metodos para tratamiento de tumores.
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
GEP20156341B (en) Anticoagulant antidotes
WO2014055543A3 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
MX2014013752A (es) Inhibidores de nampt.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
NZ603773A (en) Asparaginase from basidiomycetes
MX348311B (es) Inhibidores nampt.
EA201300688A1 (ru) Новая форма введения ингибитора энкефалиназы
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
IN2014DN08385A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal